Objectives: To describe recruitment, screening and baseline characteristics of injection drug users (IDU) participating in a phase III HIV vaccine (AIDSVAX 1 B/E; VaxGen, USA) trial and to compare enrollment characteristics between trial participants and 1209 IDU from a 1995-1998 vaccine trial preparatory cohort for changes that might impact trial design assumptions.
Introduction
Phase III vaccine efficacy trials have traditionally been conducted in populations at highest risk for infection. This is done to increase trial efficiency and to test the vaccine in populations likely to be targeted for immunization after licensing. For HIV vaccines, this strategy has been challenged as many of those at highest risk [injection drug users (IDU), commercial sex workers, and men who have sex with men] may not want to be identified because of concerns about stigmatization, discrimination, or the illegal nature of their activities. In addition, such persons may choose not to participate because of lack of trust in the sponsoring institution, the long-term commitment requested or other trial requirements.
The Thai HIV epidemic among IDU began in 1988, when prevalence rose from , 1% to . 40% [1] . In 1991, an HIV vaccine development program was initiated to support establishing vaccine preparatory cohorts and to develop the infrastructure and technical capacity to conduct large-scale HIV vaccine efficacy trials [2, 3] . In response, the Royal Thai Government's National Plan for HIV/AIDS included a vaccine development and evaluation component [4] . From 1995 to 1998, an HIV vaccine preparatory cohort study of 1209 IDU was conducted to determine the feasibility of performing a phase III trial in this group. This cohort revealed an annual HIV incidence rate of 5.8/100 person-years, high follow-up rates (. 70% at 36 months) [5] and willingness of IDU to participate in HIV vaccine trials [6] ; it also defined the clinical course of HIV infection in this population [7, 8] . In addition, an HIV subtype distribution of 20.8% B and 79.2% E (circulating recombinant form 01_AE) was found [9, 10] . Based on these findings, a recombinant gp120 vaccine was developed composed of antigens from HIV subtype B (MN) and subtype E (A244) (AIDSVAX 1 B/E, VaxGen, Brisbane, California, USA) [11, 12] . A 1998 phase I/II trial of this vaccine showed it to be immunogenic and safe [13] . In 1999, a phase III trial to evaluate the safety and efficacy of the AIDSVAX 1 B/E vaccine was initiated.
This paper describes the vaccine trial's recruitment methods, screening and enrollment, and the baseline characteristics of participants. It compares these with those of preparatory cohort participants to look for any changing epidemiological factors that might impact trial design assumptions.
Methods
Trial design This is a randomized, double-blinded, placebocontrolled trial. Enrolled volunteers were randomly assigned to receive either AIDSVAX 1 B/E vaccine or placebo (1:1 ratio) at months 0, 1 and 6, with boosters at months 12, 18, 24 and 30. Assuming a 4% annual HIV incidence rate in 2500 IDU over 3 years, the trial is designed to detect vaccine efficacy with a lowerbound 95% confidence interval (CI) of 30% (point estimate 67%). The primary endpoint was HIV infection measured by enzyme-linked immunoassay (EIA) and Western blot and the secondary endpoint was mitigation of disease measured by viral load and CD4 cell count. At enrollment and every 6 months thereafter, standardized questionnaires were administered, and an HIV test was performed. HIV-infected participants were followed-up every 4 months and receive care according to Bangkok Metropolitan Administration (BMA) treatment guidelines, which now include three antiretroviral drugs for a CD4 cell count , 200 3 10 6 cells/l or for symptomatic infection [14] . Screening and enrollment IDU known to be HIV seropositive were not screened for enrollment. Eligibility criteria included completion of informed consent, possession of a Thai national identification card, age 20-60 years, availability for 3 years' follow-up, history of injection drug use in the previous year, and willingness to receive HIV counseling and testing. IDU screening seropositive (Genetic System HIV1/HIV2 EIA, Sanofi Pasteur Diagnostics, Genetic Systems Corporation, Washington, USA; confirmatory Western blot, NOVAPATH HIV-1 Immunoblot, Biorad Laboratories, California, USA) were excluded from enrollment; HIV subtype distribution among these screening specimens was determined by V3 loop peptide EIA [15] .
Study setting
Trained counselors provided further HIV education to remaining eligible IDU during individual and group sessions, with assistance of audiovisual and written materials. In addition, these potential participants were tested to assess comprehension of trial concepts [16, 17] , including: (i) vaccine-induced antibody may cause a false-positive HIV antibody test; (ii) the HIV vaccine may lead to faster disease progression in those who become HIV infected; (iii) volunteers will not know whether they received vaccine or placebo; and (iv) it is not known whether the vaccine provides protection.
To pass the test, volunteers had to respond correctly to 80% of true-false questions and to several critical concepts. They were allowed two attempts. Those who passed provided a medical history and received a physical examination to ensure they satisfied medical criteria. Healthy, consenting HIV-seronegative IDU were enrolled.
Education and counselling
Comprehensive education and risk behavior counseling were provided at every study visit, as described elsewhere in this issue [18] .
Ethical approval
The trial protocol was approved by Thailand's National AIDS Committee; the Ethical Review Committee of the Thailand MOPH; the Institutional Review Boards of Mahidol University, BMA, and CDC; the US Office for Human Research Protection; the US Food and Drug Administration; and UNAIDS, Geneva, Switzerland.
Preparatory cohort study
The methods and characteristics of the preparatory cohort enrolled in 1995 and 1996, and followed through 1998 are published elsewhere [5, 19] .
Statistics
Cohort and trial participant enrollment characteristics were compared using chi-square or Fisher's exact test for categorical variables and the t test or Wilcoxon rank sum test for continuous variables. Adjusted odds ratios and 95% confidence intervals were estimated using multiple logistic regression; factors significant (P , 0.1) on univariate analyses were retained in the model.
Results
From e Because of collinearity, the frequency of any injection was evaluated instead of history of heroin, stimulant or tranquilizer/ hypnotic injection, because frequency of injection is a more precise indicator of risk.
the previous 6 months, 82.2% had received methadone treatment [18] . A history of ever having been incarcerated (jail or prison) was reported by 1996 (78.4%), and 446 (17.5%) had been incarcerated at least once in the previous 6 months; of these, 58 (13.0%) injected drugs while incarcerated.
The median number of sex partners in the 6 months prior to enrollment was 1.0, and 860 (33.8%) were living with a heterosexual partner; of these, 19.7% reported sexual intercourse less than once a month and 20.8% used condoms with this partner. For the 348 IDU who reported having sex with a casual partner, condom use was common (46.0% always, 16.4% irregular, 37.6% never). Sharing needles/syringes with a sexual partner was reported by 82 (3.2%) participants, and having sex with a person of the same sex was reported by 23 (0.9%) participants.
Significant univariate comparisons between trial and cohort IDU are found in Table 2 . Multivariable analysis showed vaccine trial IDU to be younger, better educated, less likely to inject daily, and less likely to have sex with their live-in sexual partners than the preparatory cohort IDU (all P < 0.0001) ( Table 2) . Trial IDU were more likely to have a history of incarceration, obtain needles and syringes from a source other than a pharmacist, more than twice as likely to inject stimulants, and nearly five times as likely to inject tranquilizers (all P < 0.003).
Discussion
The world's first HIV vaccine efficacy trial in a developing country has been successfully initiated in Bangkok, Thailand. In designing the vaccine trial, it was important to be conservative in estimating HIV incidence. Because we anticipated that the intensive education, counseling and interventions unrelated to vaccine would reduce risk behavior, we assumed a 4% incidence of HIV infection for vaccine trial participants based on an incidence of 6% from the 1995-1998 preparatory cohort [5] .
Traditional modes of trial recruitment such as media messages, flyers and posters were not effective tools, accounting for only 0.8% of those who enrolled. Most recruitment contacts occurred in BMA narcotic clinics, followed by IDU referral programs and through previous cohort participation, demonstrating an atmosphere of trust between BMA staff and IDU and the importance of IDU involvement in trial preparation. Similar to other HIV vaccine trials, among men who have sex with men in the United States [20] , altruism was a prominent motivation, cited by 95.8% of IDU. Other motivations such as HIV testing, physical examinations and HIV information were important and should be considered in the design of vaccine trials among IDU.
The finding that 32.4% of IDU screened for enrollment were HIV seropositive highlights the urgent need for an effective HIV vaccine in this population. At the time of enrollment, HIV-seronegative IDU reported high-risk behaviors strongly associated with HIV transmission. Although incarcerated IDU were not recruited or enrolled into the trial, participants who became incarcerated during follow-up were retained [18] . Because incarceration may be associated with incident HIV infection through multiple pathways [21] , riskbehavior counseling was intensified during follow-up with incarcerated volunteers. Reports of frequently injecting drugs and sharing needles while incarcerated indicate that recruitment efforts to identify high-risk IDU have been successful. However, they also point out the need for intensive risk-reduction counseling, together with free condoms and bleach at every study visit. Trial participants do not report problems obtaining sterile needles and syringes, as they are cheap and widely available. Risk-behavior trends are being evaluated throughout the trial, and education/counseling procedures are being modified when necessary [18] .
The finding that trial volunteers were younger, better educated and injected drugs less frequently than cohort IDU suggests, on the one hand, that IDU choosing to participate in a vaccine trial may be more informed about risks for HIV infection and more motivated to enroll. On the other hand, trial participants were more likely to inject tranquilizers and hypnotics, indicating that drug use habits may be changing because of decreasing availability and increasing price for heroin [18] . Although some characteristics between preparatory cohort and trial participants did differ, these differences do not appear to affect the statistical power, trial design or ability to determine definitively the protective efficacy of the AIDSVAX 1 B/E vaccine.
In HIV vaccine trial preparations, determination of HIV subtype(s) of incident strains is important to ensure a reasonable match between vaccine and circulating viruses [22] . The explosive HIV epidemic among Bangkok IDU in 1988 was almost solely with subtype B [1] . Subsequent cross-sectional studies in the early 1990s suggested a change from subtype B to subtype E [19, 23, 24] . Throughout the 1995-1998 preparatory cohort period, the proportion of HIV subtypes among incident infections was stable (20% B and 80% E) [5, 9] . The HIV subtype distribution among IDU testing positive at trial screening (25% B and 75% E) supports the use of bivalent AIDSVAX 1 B/E in this population.
for the design and conduct of the vaccine efficacy trial. This cohort helped to determine long-term incidence trends and what would be an adequate trial population size for sufficient statistical power to evaluate vaccine efficacy. In addition, the preparatory cohort showed the willingness of IDU to participate, the distribution of circulating HIV subtypes and the appropriate antigens for inclusion in the vaccine; it also strengthened the public health and research institution capacity to conduct this trial in Thailand. Finally, although the efficacy of AIDSVAX 1 B/E is still yet to be determined, this trial has clearly demonstrated that IDU at high risk for HIV can be enrolled in sufficient numbers in a large-scale field trial. Final trial results are expected in late 2003.
